Prognostic role of the PET parameter maximum standardized uptake value in non small cell lung cancer: Analysis in tumour of diameter ≥ and <25 mm

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 1, 2011, Pages 72-80

  Pelosi, E ^a   Bille A ^b   Skanjeti, A ^a,c   Errico, L ^b   Arena, V ^a   Ardissone, F ^b   Borasio, P ^b   Mancini, M ^a  

^a Via Onorato Vigliani   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

Carcinoma; Non small cell lung; Positron emission tomography; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ARTICLE; ARTIFACT; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; STANDARDIZATION; TUMOR NECROSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 79957468325     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Lee P, Colt HG. State of the art: pleuroscopy. J Thorac Oncol 2007;2:663-70. (Pubitemid 47171792)
2. Hicks RJ, Lau E, Alam NZ, Chen RY. Imaging in the diagnosis and treatment of non-small cell lung cancer. Respirology 2007;12:165-72.
3. Mac Manus M, Hicks RJ, Everitt S. Role of PET-CT in the optimization of thoracic radiotherapy. J Thorac Oncol 2006;1:81-4. (Pubitemid 47164027)
4. Eschmann SM, Friedel G, Paulsen F, Reimold M, Hehr T, Budach W et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:463-71. (Pubitemid 46426996)
5. Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, BenNun A et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004;45:1640-6. (Pubitemid 47618469)
6. Pauwels EK, Sturm EJ, Bombardieri E, Cleton FJ, Stokkel MP. Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 2000;126:549-59.
7. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53:233-56. (Pubitemid 47074647)
8. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of [18F]FDG-PET in non-small cell lung cancer: a systematic review. Cancer 2007;110:1654-64.
9. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
10. Lucignani G, Paganelli G, Bombardieri E. The use of standardized uptake values for assessing [18F]FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun 2004;25: 651-6.
11. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non small cell lung carcinoma. Cancer 1998;83:918-24. (Pubitemid 28401925)
12. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. J Clin Oncol 1999;17:3201-6.
13. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136-43. (Pubitemid 46202269)
14. Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000;18: 425-8.
15. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-6.
16. Jeong HJ, Min JJ, Park JM, Chung JK, Kim BT, Jeong JM et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23: 865-70.
17. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA et al. Standardised [18F]FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005;41:1533-41. (Pubitemid 40981834)
18. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45. (Pubitemid 34101186)
19. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE 2nd, Patz EFJr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459-64.
20. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005;130:151-9. (Pubitemid 40941684)
21. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13:3255-63.
22. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3: 6-12.
23. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. New York, NY: Springer, 2002; p. 165-77.
24. Nabi HA, Zubeldia JM. Clinical applications of (18)F-FDG in oncology. J Nucl Med Technol 2002;30:3-9.
25. van Rens MT, de la Rivière AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000;117:374-9. (Pubitemid 30111585)
26. Birim O, Kappetein AP, van Klaveren RJ, Bogers AJ. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 2006;32: 12-23. (Pubitemid 43103982)
27. Sasaki M, Sugio K, Kuwabara Y, Koga H, Nakagawa M, Chen T et al. Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased [18F]FDG uptake in lung cancer. Ann Nucl Med 2003;17:189-19.
28. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M et al. [18F]FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000;41:85-92. (Pubitemid 30046688)
29. Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y et al. [18F]FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000;21:707-14.
30. Pillot G, Siegel BA, Govindan R. Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review. J Thorac Oncol 2006;1:152-9. (Pubitemid 47164003)
31. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with [18F]FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 2002;26:185-90. (Pubitemid 34233362)
32. van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-lalpha and GLUT1 in non-small cell lung cancer. Eur J Cancer 2007;43:1392-8.
33. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44.
34. de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF et al. Biological correlates of [18F]FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79-87.
35. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Gluti and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997;80:1046-51. (Pubitemid 27427603)
36. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45. (Pubitemid 46909922)
37. Erdi YE, Nehmeh SA, Pan T, Pevsner A, Rosenzweig KE, Mageras G et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med 2004;45:1287-92. (Pubitemid 47618524)
38. Alkhawaldeh K, Bural G, Kumar R, Alavi A. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2008;35:246-5.
39. Weber WA, Czernin J, Phelps ME. Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture? Clin Cancer Res 2007;13:3105-6. (Pubitemid 46944889)
40. Bettinardi V, Danna M, Savi A, Lecchi M, Castiglioni I, Gilardi MC et al. Performance evaluation of the new whole-body PET/CT scanner: Discovery ST. Eur J Nucl Med Mol Imaging 2004;31:867-88.